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2013 at the Institute of Cardiology, Warsaw, Po­
land from among stable hospitalized or ambula­
tory patients. The diagnosis of HCM was based 
on the presence of unexplained myocardial hy­
pertrophy (in the absence of abnormal loading 
conditions) assessed as maximal left ventricu­
lar wall thickness of 15 mm or more, or in ac­
cordance with the criteria for the diagnosis of 
familial disease in patients with at least 1 first­
­degree relative with HCM.
Venous blood samples were obtained from all 
patients. Plasma NT ­proBNP level was measured 
by 2­site electrochemiluminescence immunoas­
say on the Cobas e601 analyzer (Roche Diagnos­
tics, Indianapolis, Indiana, United States). Re­
sults were reported in pg/ml. Normal values for 
the assay (0.00–125.00 pg/ml) were defined us­
ing manufacturer’s guidelines.
The primary endpoint consisted of all ­cause 
mortality or heart transplantation. Two second­
ary endpoints included: 1) unscheduled hospi­
talization due to deterioration of heart failure, 
and 2) resuscitated sudden cardiac death (SCD) 
or appropriate intervention of the implanted 
cardioverter ­defibrillator (ICD). Data on ICD 
intervention were obtained from device inter­
rogation reports. Statistical analysis was per­
formed using the SPSS package (version 20.0, 
IBM Corporation, Armonk, New York, United 
States). The study was approved by the local eth­
ics committee.
Results and discussion The study included 603 
patients with HCM (57.5% men, mean [SD] age, 
Introduction Hypertrophic cardiomyopathy 
(HCM) is a common inherited heart disease oc­
curring in about 1 in 500 people in the general 
population. In a majority of cases HCM is caused 
by mutations in genes encoding sarcomere pro­
teins. The disease leads to disarray of cardio­
myocytes with secondary interstitial fibrosis, 
resulting in myocardial hypertrophy with dia­
stolic and systolic dysfunctions.1
B ­type natriuretic peptide (BNP) is a poly­
peptide secreted by the ventricular muscle in 
response to excessive stretching of cardiomy­
ocytes. Its levels are elevated in patients with 
heart failure, including those with left ventric­
ular outflow tract obstruction at rest or diastol­
ic dysfunction.2 BNP or N ­terminal fragment of 
pro ­BNP (NT ­proBNP) levels are elevated in pa­
tients with HCM also due to silent myocardial 
ischemia or an end ­stage form of HCM repre­
sented by systolic heart failure.3 The levels of 
these peptides correlate with functional class 
assessed according to the New York Heart As­
sociation (NYHA) classification.4
Both BNP and NT ­proBNP are clinically im­
portant diagnostic and prognostic markers of 
ischemic heart disease and heart failure, but 
the usefulness of these biomarkers for risk strat­
ification in HCM is unclear. The present investi­
gation was set to determine the prognostic util­
ity of NT ­proBNP in patients with HCM.
Methods This was an observational, prospec­
tive, single ­center cohort study. Participants 
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heart failure followed by an unplanned hospi­
talization (P = 0.003).
NT ­proBNP levels below the cutoff point for 
the detection of heart failure (<125 pg/ml) were 
found in 84 patients (14% of the whole group). Mean 
(SD) age in this group of patients was 31 (11) years. 
Among those patients there was only a single hos­
pitalization due to exacerbation of heart failure. All 
of these patients were initially in NYHA class I or II.
We demonstrated that NT ­proBNP is an in­
dependent predictor of worse clinical outcome 
in patients with HCM. These results are in line 
with a previous large prospective study including 
847 HCM patients.4 Another retrospective anal­
ysis on 772 patients showed that higher levels 
of BNP correlate with all ­cause mortality.5 Both 
BNP and NT ­proBNP were found to be markers 
of worse prognosis in few previously published 
small studies.6-10 Our study strongly supports 
previous findings.
We demonstrated that patients with HCM who 
were in the lowest tertile of NT ­proBNP concen­
trations, and particularly those with biomarker 
levels below the cutoff point for heart failure de­
tection (<125 pg/ml), have generally good prog­
nosis, as demonstrated by lack of deaths or heart 
transplantations as well as by a small number 
of unscheduled hospitalizations in this group 
of patients. Furthermore, the baseline NYHA 
class in this group of patients with HCM was 
also lower than in patients in the higher tertiles 
of NT­proBNP concentrations. Therefore, these 
patients can be considered as a low ­risk group, 
provided they are thoroughly screened for the in­
creased risk of SCD and receive an ICD if neces­
sary (we reported 2 appropriate device interven­
tions in this group of patients).
Our study has some limitations. First of all, 
the results are based on a single NT ­proBNP mea­
surement. However, other studies in that area 
also did not use repetitive biomarker sampling. 
Secondly, the primary endpoint occurred in a rel­
atively small number of patients. This was main­
ly influenced by 2 facts: the relatively short pe­
riod of follow ­up and a high frequency of prior 
ICD implantations in the study group. The de­
vice was present at baseline in 28% of patients 
in our group and only in 12% of patients in a pre­
viously reported large study.4
We found that the NT ­proBNP concentra­
tion is not a predictor of SCD or appropriate 
ICD interventions. These data suggest that this 
biomarker cannot be considered a useful risk 
factor for better identification of high ­risk pa­
tients who may benefit from ICD implantation 




CONFLICT OF INTEREST None declared.
44 [17] years). Median plasma NT ­proBNP con­
centration in the whole group was 836.3 pg/ml 
(interquartile range [IQR], 289.57–1699.25 pg/
ml). NT ­proBNP values were higher in women 
than in men (P = 0.028). For the purpose of this 
analysis, patients in the second and third tertiles 
of NT ­proBNP concentrations (300–1700 pg/ml 
and >1700 pg/ml) were compared with those in 
the first tertile (<300 pg/ml). Patients in the high­
er tertiles of NT ­proBNP concentrations had 
worse NYHA functional class. NT ­proBNP lev­
els were measured in peripheral blood at base­
line. Patients were observed for a mean (SD) of 
27 (14) months. Primary end point occurred in 
14 patients (2.3%) and included 11 deaths and 
3 heart transplantations. Fatal events included 
9 deaths due to deterioration of heart failure, 1 
SCD, and 1 death due to post operative compli­
cations. Secondary end points occurred in: 1) 32 
patients (5.4%) and 2) 23 patients (3.7%), respec­
tively. The latter included 1 resuscitated SCD and 
22 appropriate ICD interventions.
Patients in the higher tertiles of NT ­proBNP 
concentrations had a higher risk of death or 
heart transplantation (hazard ratio [HR], 5.9; 
95% CI, 2.05–17.04; P = 0.001) and unscheduled 
hospitalizations due to heart failure (HR, 1.76; 
95% CI, 1.03–3.0, P = 0.037) as determined by 
the multivariable Cox model. Sudden cardiac 
death or appropriate ICD intervention was not 
significantly associated with higher levels of NT­
­proBNP. There were no primary events and only 
a few appropriate ICD interventions in those in 
the lowest tertile of NT ­proBNP levels.
Patients with NT ­proBNP in the second and 
third tertiles had worse survival rates in com­
parison to those in the first tertile of the NT­
­proBNP concentrations (P = 0.007) (FIGURE 1). They 
also had an increased risk of deterioration of 
FIGURE 1 Kaplan –Meier curve for the primary endpoint according to tertiles of N ‑terminal 
pro ‑brain natriuretic peptide (NT‑proBNP) concentration

































<300 pg/mlP = 0.003
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